XXII

22nd Century Group
XXII
Market cap $1.01M

2.94 USD

-0.11

3.61%

At close Jul 30, 4:00 PM EDT

After hours

2.98

+0.04

1.36%

1 day

-3.61%

5 days

-1.34%

1 month

-60.96%

3 months

-84.96%

6 months

-96.85%

Year to date

-97.72%

1 year

-99.87%

5 years

-100.00%

10 years

-100.00%

About: 22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.

Employees: 56

Consumer Staples Tobacco

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

22% more capital invested

Capital invested by funds: $299K [Q4 2024] → $364K (+$64.6K) [Q1 2025]

10% more funds holding

Funds holding: 31 [Q4 2024] → 34 (+3) [Q1 2025]

0.42% more ownership

Funds ownership: 10.25% [Q4 2024] → 10.66% (+0.42%) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for XXII.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about XXII published over the past 30 days

22nd Century Applauds the American Academy of Family Physicians Comments and Support of the FDA's Proposed Reduced Nicotine Mandate to Reduce Smoking, Transform Public Health, Save Lives and Reduce Health Costs

22nd Century VLN ® products are the only combustible cigarettes authorized by the FDA as a reduced nicotine content product that comply with the FDA proposed rule MOCKSVILLE, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction, today commented on responses provided to the U.S. Food and Drug Administration to date as part of its open comment period on the proposed new Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products.

22nd Century Applauds the American Academy of Family Physicians Comments and Support of the FDA's Proposed Reduced Nicotine Mandate to Reduce Smoking, Transform Public Health, Save Lives and Reduce Health Costs

22nd Century Reports Expanded State Authorization Progress to Sell VLN®, Partner VLN® and Conventional Products

State Authorizations Mean Even More Adult Smokers Will Be Able to Purchase VLN ® , Partner VLN ® , Smoker Friendly and Pinnacle Products

22nd Century Reports Expanded State Authorization Progress to Sell VLN®, Partner VLN® and Conventional Products

VLN Commercial Launches Confirm Viability of the FDA's Proposed Reduced Nicotine Mandate

Multiple Tobacco Brands Partnering with 22nd Century to Expand Availability and Awareness of VLN Based Reduced Nicotine Content Products

VLN Commercial Launches Confirm Viability of the FDA's Proposed Reduced Nicotine Mandate

22nd Century Provides Corporate Update On Its VLN® MRTP Renewal Process – The First and Only Combustible Tobacco Product Authorized by the FDA Specifically to Help Smokers Smoke Less

Extensive Clinical Data Continues to Demonstrate VLN ® Reduced Nicotine Content Tobacco Helps Reduce Smoking and Increase Quit Attempts Growing List of VLN ® Based Cigarette Brands Bring Non-Addictive Alternatives to the Fight Against Smoking MOCKSVILLE, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that has for 27 years led and continues to lead the fight against the harms of smoking driven by nicotine addiction today announces a corporate update regarding its Modified Risk Tobacco Product renewal process for its innovative VLN® reduced nicotine content products - the first and only combustible cigarette authorized by the U.S. Food and Drug Administration specifically to reduce the health harms of smoking.

22nd Century Provides Corporate Update On Its VLN® MRTP Renewal Process – The First and Only Combustible Tobacco Product Authorized by the FDA Specifically to Help Smokers Smoke Less

22nd Century Announces Operation 100 – A 100mm VLN® Cigarette Designed to Reach Even More Adult Smokers Who Want to Reduce Their Nicotine Consumption

100mm Cigarettes Comprise Approximately Half the U.S. Market, Giving Even More Smokers a Familiar Choice as They Seek Ways to Change Their Smoking Behavior First FDA Submission Planned for Q4 2025 MOCKSVILLE, N.C.,, June 26, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced the advancement of a 100mm VLN® reduced nicotine content cigarette.

22nd Century Announces Operation 100 – A 100mm VLN® Cigarette Designed to Reach Even More Adult Smokers Who Want to Reduce Their Nicotine Consumption

22nd Century Announces Second Partner VLN Product Deal as Part of Major Pinnacle Brand Expansion Agreement with Top-5 C-Store Chain

Launching New Pinnacle VLN and Moist Snuff Products in More Than 1,700 Stores Across 27 States MOCKSVILLE, N.C., June 24, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), the only tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced major updates to its Pinnacle product manufacturing and marketing agreement with its top-5 c-store chain customer, including the launch of four new Pinnacle SKUs, including two in the low nicotine product category.

Top 3 Risk Off Stocks That Could Blast Off This Month

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Top 3 Risk Off Stocks That Could Blast Off This Month

Emerging Growth Research Releases Q1 2025 Update Report on 22nd Century Group

New York, New York--(Newsfile Corp. - May 21, 2025) - Emerging Growth Research today released its latest quarterly update report on 22nd Century Group, Inc. (NASDAQ: XXII), following the Company's Q1 2025 results. The report reflects the continued operational progress made under new management and the outlook for meaningful financial improvement in 2025.

Emerging Growth Research Releases Q1 2025 Update Report on 22nd Century Group

22nd Century to Present at the Emerging Growth Conference on May 21, 2025

MOCKSVILLE, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, (the “Company”) is pleased to announce that Larry Firestone, Chief Executive Officer, will present a brief corporate update at the Emerging Growth Conference on Wednesday, May 21, 2025, at 12:00 pm Eastern Time.

22nd Century to Present at the Emerging Growth Conference on May 21, 2025

22nd Century Group, Inc. (XXII) Q1 2025 Earnings Call Transcript

22nd Century Group, Inc. (NASDAQ:XXII ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Matt Kreps - IR Larry Firestone - CEO Dan Otto - CFO Conference Call Participants Andrew White - Emerging Growth Research Operator Welcome to 22nd Century Group's First Quarter 2025 Conference Call and Webcast. At this time, all participants have been placed in a listen-only mode.

22nd Century Group, Inc. (XXII) Q1 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™